These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

432 related articles for article (PubMed ID: 34683370)

  • 21. Combining antibiotics with antivirulence compounds can have synergistic effects and reverse selection for antibiotic resistance in Pseudomonas aeruginosa.
    Rezzoagli C; Archetti M; Mignot I; Baumgartner M; Kümmerli R
    PLoS Biol; 2020 Aug; 18(8):e3000805. PubMed ID: 32810152
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Development of quorum-based anti-virulence therapeutics targeting Gram-negative bacterial pathogens.
    Tay SB; Yew WS
    Int J Mol Sci; 2013 Aug; 14(8):16570-99. PubMed ID: 23939429
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recent Advances in Anti-virulence Therapeutic Strategies With a Focus on Dismantling Bacterial Membrane Microdomains, Toxin Neutralization, Quorum-Sensing Interference and Biofilm Inhibition.
    Fleitas Martínez O; Cardoso MH; Ribeiro SM; Franco OL
    Front Cell Infect Microbiol; 2019; 9():74. PubMed ID: 31001485
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Optimizing antibiotic therapies to reduce the risk of bacterial resistance.
    Bassetti S; Tschudin-Sutter S; Egli A; Osthoff M
    Eur J Intern Med; 2022 May; 99():7-12. PubMed ID: 35074246
    [TBL] [Abstract][Full Text] [Related]  

  • 25. New Insights into Autoinducer-2 Signaling as a Virulence Regulator in a Mouse Model of Pneumonic Plague.
    Fitts EC; Andersson JA; Kirtley ML; Sha J; Erova TE; Chauhan S; Motin VL; Chopra AK
    mSphere; 2016; 1(6):. PubMed ID: 27981238
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Impact of vaccines on antimicrobial resistance.
    Buchy P; Ascioglu S; Buisson Y; Datta S; Nissen M; Tambyah PA; Vong S
    Int J Infect Dis; 2020 Jan; 90():188-196. PubMed ID: 31622674
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Targeting bacterial pathogenesis by inhibiting virulence-associated Type III and Type IV secretion systems.
    Blasey N; Rehrmann D; Riebisch AK; Mühlen S
    Front Cell Infect Microbiol; 2022; 12():1065561. PubMed ID: 36704108
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Pathogenicity of Enterococci].
    Ike Y
    Nihon Saikingaku Zasshi; 2017; 72(2):189-211. PubMed ID: 28659548
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Corynebacterium pseudodiphtheriticum Exploits Staphylococcus aureus Virulence Components in a Novel Polymicrobial Defense Strategy.
    Hardy BL; Dickey SW; Plaut RD; Riggins DP; Stibitz S; Otto M; Merrell DS
    mBio; 2019 Jan; 10(1):. PubMed ID: 30622190
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Subinhibitory Concentrations of Antibiotics Exacerbate Staphylococcal Infection by Inducing Bacterial Virulence.
    Gao P; Wei Y; Wan RE; Wong KW; Iu HTV; Tai SSC; Li Y; Yam HCB; Halebeedu Prakash P; Chen JHK; Ho PL; Yuen KY; Davies J; Kao RYT
    Microbiol Spectr; 2022 Aug; 10(4):e0064022. PubMed ID: 35758685
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Breaking antimicrobial resistance by disrupting extracytoplasmic protein folding.
    Furniss RCD; Kaderabkova N; Barker D; Bernal P; Maslova E; Antwi AAA; McNeil HE; Pugh HL; Dortet L; Blair JMA; Larrouy-Maumus G; McCarthy RR; Gonzalez D; Mavridou DAI
    Elife; 2022 Jan; 11():. PubMed ID: 35025730
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antibiotic Degradation by Commensal Microbes Shields Pathogens.
    Gjonbalaj M; Keith JW; Do MH; Hohl TM; Pamer EG; Becattini S
    Infect Immun; 2020 Mar; 88(4):. PubMed ID: 31964746
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Virulence blockers as alternatives to antibiotics: type III secretion inhibitors against Gram-negative bacteria.
    Keyser P; Elofsson M; Rosell S; Wolf-Watz H
    J Intern Med; 2008 Jul; 264(1):17-29. PubMed ID: 18393958
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-antibiotic methods against Pseudomonas aeruginosa include QS inhibitors: a narrative review.
    Xiang Y; Ding Y; Cao J; Sun Y; Wang F; Ju S; Yu J
    Ann Palliat Med; 2021 Jun; 10(6):6926-6935. PubMed ID: 34044573
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Strategies to prevent the occurrence of resistance against antibiotics by using advanced materials.
    Bassegoda A; Ivanova K; Ramon E; Tzanov T
    Appl Microbiol Biotechnol; 2018 Mar; 102(5):2075-2089. PubMed ID: 29392390
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Antimicrobial peptides properties beyond growth inhibition and bacterial killing.
    Castillo-Juárez I; Blancas-Luciano BE; García-Contreras R; Fernández-Presas AM
    PeerJ; 2022; 10():e12667. PubMed ID: 35116194
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stable antibiotic resistance and rapid human adaptation in livestock-associated MRSA.
    Matuszewska M; Murray GGR; Ba X; Wood R; Holmes MA; Weinert LA
    Elife; 2022 Jun; 11():. PubMed ID: 35762208
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Investigational therapies targeting quorum-sensing for the treatment of Staphylococcus aureus infections.
    Khan BA; Yeh AJ; Cheung GY; Otto M
    Expert Opin Investig Drugs; 2015 May; 24(5):689-704. PubMed ID: 25704585
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The Population Genomics of Increased Virulence and Antibiotic Resistance in Human Commensal Escherichia coli over 30 Years in France.
    Marin J; Clermont O; Royer G; Mercier-Darty M; Decousser JW; Tenaillon O; Denamur E; Blanquart F
    Appl Environ Microbiol; 2022 Aug; 88(15):e0066422. PubMed ID: 35862685
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Anti-virulence therapeutic strategies against bacterial infections: recent advances.
    Dehbanipour R; Ghalavand Z
    Germs; 2022 Jun; 12(2):262-275. PubMed ID: 36504617
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.